Reviewed November 16, 2026
Ro
PrivateDirect-to-consumer telehealth
Company overview
- Revenue
- ~$3.02B run rate
- October 2026 · Estimate
- Reference valuation
- $7B
- Historical financing · Feb 2022
- Primary customer
- Patients seeking weight management[1]
- Commercial model
- Telehealth and medication-related revenue[1]
Revenue is an independently estimated measure. The valuation is a dated transaction reference, not a current appraisal.[1]
Revenue history
Revenue
Annualized revenue · USD
+1,158%
Oct 2026 vs. Dec 2022 · calculated change; not annualized
| Period | USD | Evidence |
|---|---|---|
| $240M | Estimate | |
| $258M | Estimate | |
| $526M | Estimate | |
| $875M | Estimate | |
| $3.02B | Estimate |
Sacra · company research and financial history ↗
Annualized revenue observations are point-in-time measures, not completed annual revenue.
Points show dated observations at equal spacing; intervening performance is not measured.
Products, customers & revenue model
Business economics
- What drives the business
- The revenue recovery followed the GLP-1 expansion. Medication-related sales should not be treated as software revenue.[1]
Leadership & functional coverage
Selected leaders supported by the linked sources; dated appointments retain their source context. This is not a complete org chart. Advisory roles are labeled.
| Leader | Role | Function / context |
|---|---|---|
| Zach Reitano | Cofounder & CEO | Company leadership[2] |
| Sam Chai | VP, Clinical Strategy & Scientific Affairs | Clinical strategy[3] |
| Casey Stackwick | Senior Director, Pharmacy Operations | Pharmacy operations[3] |
| Scott Bachand | CIO / CISO | IT & security · June 2026 event[4] |
Dated financial disclosures
Sector comparison
Same vertical; different business models and reporting periods. Values are not directly comparable revenue multiples.
| Company | Revenue measure | Reference valuation |
|---|---|---|
| Ro | ~$3.02B run rate October 2026 | $7B Feb 2022 |
| Devoted Health | ~$3.27B revenue FY2024 | $25B Oct 2026 |
| OpenEvidence | ~$300M run rate July 2026 | $15B Sep 2026 |
| Commure | ~$105M ARR March 2024 | $7B May 2026 |
| Abridge | ~$100M ARR May 2025 | $5.3B Jun 2025 |
Open research questions
- ↗What contribution margin remains after medications, care delivery and acquisition costs?
Sources & definitions
Financial history preserves the source’s measurement basis. ARR, annualized revenue, completed-year sales and transaction volume are distinct. Product economics are Plank analysis of the cited business model; open questions are not asserted findings.